文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

拉那利尤单抗对比安慰剂预防遗传性血管性水肿发作的随机临床试验

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

这项3期随机双盲安慰剂对照试验在加拿大、欧洲、约旦和美国41个中心纳入125例12岁及以上I或II型遗传性血管性水肿患者,按2:1随机分配至拉那利尤单抗或安慰剂,拉那利尤单抗组再按1:1:1分为3种剂量方案,治疗26周。结果显示,与安慰剂相比,拉那利尤单抗各剂量方案均显著降低每月发作率,最常见的不良事件为注射部位反应和头晕。

要点

  • 拉那利尤单抗26周治疗显著降低I或II型遗传性血管性水肿每月发作率。
  • 每2周300mg方案每月发作率0.26,安慰剂组为1.97。
  • 注射部位反应和头晕在拉那利尤单抗组更常见。

核心结论

  • 在I或II型遗传性血管性水肿患者中,皮下注射拉那利尤单抗26周较安慰剂显著降低发作率,支持其作为预防性治疗。

研究设计与样本

  • 3期随机双盲平行组安慰剂对照试验,在加拿大、欧洲、约旦和美国41个中心开展,2016年3月3日至9月9日随机,末次随访2017年4月13日。
  • 125例12岁及以上I或II型遗传性血管性水肿患者,经历4周导入期且导入期内至少1次发作后随机,按2:1分配至拉那利尤单抗或安慰剂,拉那利尤单抗组再按1:1:1分为3种剂量方案。
  • 治疗26周:拉那利尤单抗150mg每4周(n=28)、300mg每4周(n=29)、300mg每2周(n=27)或安慰剂(n=41);所有患者每2周注射一次,每4周组在活性治疗间期接受安慰剂。

主要发现

  • 导入期每月平均发作次数:安慰剂组4.0,150mg每4周组3.2,300mg每4周组3.7,300mg每2周组3.5。
  • 治疗期每月平均发作次数:安慰剂组1.97,150mg每4周组0.48,300mg每4周组0.53,300mg每2周组0.26。
  • 与安慰剂相比,每月发作率平均差异:150mg每4周组-1.49(95%CI,-1.90至-1.08;P<.001),300mg每4周组-1.44(95%CI,-1.84至-1.04;P<.001),300mg每2周组-1.71(95%CI,-2.09至-1.33;P<.001)。
  • 治疗组更常见的不良事件为注射部位反应(安慰剂34.1%,拉那利尤单抗52.4%)和头晕(安慰剂0%,拉那利尤单抗6.0%)。

临床怎么用

  • 对于12岁及以上I或II型遗传性血管性水肿患者,可考虑皮下注射拉那利尤单抗作为预防性治疗以减少发作。
  • 用药期间需关注注射部位反应和头晕等不良事件。

局限性

  • 需进一步研究确定长期安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current treatments for long-term prophylaxis in hereditary angioedema have limitations. OBJECTIVE: To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United States. Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12 years or older with hereditary angioedema type I or II underwent a 4-week run-in period and those with 1 or more hereditary angioedema attacks during run-in were randomized. INTERVENTIONS: Twenty-six-week treatment with subcutaneous lanadelumab 150 mg every 4 weeks (n = 28), 300 mg every 4 weeks (n = 29), 300 mg every 2 weeks (n = 27), or placebo (n = 41). All patients received injections every 2 weeks, with those in the every-4-week group receiving placebo in between active treatments. MAIN OUTCOME AND MEASURES: Primary efficacy end point was the number of investigator-confirmed attacks of hereditary angioedema over the treatment period. RESULTS: Among 125 patients randomized (mean age, 40.7 years [SD, 14.7 years]; 88 females [70.4%]; 113 white [90.4%]), 113 (90.4%) completed the study. During the run-in period, the mean number of hereditary angioedema attacks per month in the placebo group was 4.0; for the lanadelumab groups, 3.2 for the every-4-week 150-mg group; 3.7 for the every-4-week 300-mg group; and 3.5 for the every-2-week 300-mg group. During the treatment period, the mean number of attacks per month for the placebo group was 1.97; for the lanadelumab groups, 0.48 for the every-4-week 150-mg group; 0.53 for the every-4-week 300-mg group; and 0.26 for the every-2-week 300-mg group. Compared with placebo, the mean differences in the attack rate per month were -1.49 (95% CI, -1.90 to -1.08; P < .001); -1.44 (95% CI, -1.84 to -1.04; P < .001); and -1.71 (95% CI, -2.09 to -1.33; P < .001). The most commonly occurring adverse events with greater frequency in the lanadelumab treatment groups were injection site reactions (34.1% placebo, 52.4% lanadelumab) and dizziness (0% placebo, 6.0% lanadelumab). CONCLUSIONS AND RELEVANCE: Among patients with hereditary angioedema type I or II, treatment with subcutaneous lanadelumab for 26 weeks significantly reduced the attack rate compared with placebo. These findings support the use of lanadelumab as a prophylactic therapy for hereditary angioedema. Further research is needed to determine long-term safety and efficacy. TRIAL REGISTRATION: EudraCT Identifier: 2015-003943-20; ClinicalTrials.gov Identifier: NCT02586805.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018. PMID: 30480729. doi:10.1001/jama.2018.16773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。